Vyvron Review: 13 Charges a Year, Not 12

Vyvron (vyvron.com) is new. Its own testimonial section says so, in the most honest way we have seen a company put it: the patient stories are placeholders, and the site states they will appear once founding members give written consent. Take that at face value — there is no track record here yet. What there is instead is a clinical layer worth respecting, an unusually specific state disclosure, and a pricing table with two structural problems that will cost you real money if nobody points them out.

The four-week month

Vyvron's fine print says $199 per four weeks, billed every four weeks, auto-renewing until you cancel. Its marketing says "from $199/mo". Those are not the same thing. Four-week billing means 13 charges a year, not 12: at the $199 rung, a year costs $2,587 rather than the $2,388 a monthly reading implies. That is roughly an extra month of medication you did not plan for.

The unit is mislabeled rather than hidden — the disclosure is there if you find it — but every headline on the site prints "/mo", and a reader budgeting twelve payments will be short by one. Our cost model treats this as a 13-payment year, and so should yours. Auren Rx has a milder version of the same thing at 28 to 30 days, and discloses it in the same breath as the price.

There is no monthly tirzepatide plan

This is the finding that matters most and it is easy to miss. Vyvron's weight-loss table has three tiers:

Start is $199 per four weeks, billed every four weeks, and it is the only recurring rung on the page. It is semaglutide only.

Transform, badged as most popular, displays "$285/mo" and is actually $790 billed once, covering 12 weeks, of tirzepatide.

Premium displays "$248/mo" and is actually $2,981 billed once, covering a full year, of tirzepatide.

So the cheapest way to get tirzepatide from Vyvron is $790 in a single charge. There is no monthly tirzepatide rung to file, and we have not filed one. Any ranking that lists "Vyvron tirzepatide $285/mo" is quoting a display string, not a rate — a price nobody can buy for a month.

Worth noticing how that $285 is arrived at, too: $790 divided across roughly 2.77 calendar months. Divide the same $790 by three four-week cycles — the unit the rest of the site bills in — and it is $263. Two different "per month" conventions inside one table.

Founding rates, and a counter that never moves

Program pages publish founding-member rates: weight loss $199 per four weeks against a $249 list rate, microdosing $149 against $179, longevity $189 against $229. Per product, the longevity line is injectable NAD+ at $229, injectable sermorelin at $229 and injectable B12-MIC at $145.¹

The homepage program cards disagree with those pages — they show microdosing at $179, which is the post-founding list price presented as the current one, and longevity at $145, which is the cheapest single longevity SKU rather than the program rate. We treat the program pages as authoritative, because that is where the enrollment button and the billing disclosure live.

And the scarcity widget: "100 of 100 founding spots left", rendered with a full-width progress bar. It is a hardcoded constant. It will read 100 of 100 forever, however many people sign up. Nothing turns on it, but it tells you what kind of page you are reading.

The parts that are genuinely good

Clinical services run through OpenLoop Health, Inc. and its affiliated professional entities. OpenLoop is a real, substantial telehealth infrastructure company, and it is the strongest thing about this listing by some distance.

The state disclosure is better than most established providers manage: all 50 states plus DC, with a video visit required in Arkansas, DC, Delaware, Kansas, Mississippi, New Mexico, Rhode Island and West Virginia, and compounded GLP-1 explicitly unavailable in Mississippi. That is the kind of specificity you normally have to email someone for, and Auren Rx publishes none of it.

The FDA warning-letter index returned nothing for Vyvron or for OpenLoop, on a pass that correctly returned a known 2026 letter for an unrelated control seller.²

What you cannot check, and when you pay

No pharmacy is named. No prescriber is named and no NPI is published, so nothing is verifiable against the national registry. The legal entity is Vyvron, LLC at 30 N Gould St in Sheridan, Wyoming — the most heavily used registered-agent mail drop in the country, and not an operating location.

You are charged when you complete the intake, before a provider reviews it. A full refund is available only if you cancel within 72 hours with no services rendered, or if a provider medically disqualifies you. Canceling otherwise needs 72 hours' notice before the next billing date or you are charged for that cycle, and prepaid Transform or Premium plans refund only the months whose medication has not shipped — which, on a plan you paid $2,981 for up front, is the sentence to read twice.

Who this is a match for

You want semaglutide, you want it month to month, and you are comfortable being an early customer of a company with no patient history. $199 per four weeks is a fair rate for what it includes, and OpenLoop behind it is real. The microdosing program is a genuine, separately priced product rather than a marketing label — one of only two in this batch that is. And if you are in one of the eight states that require a video visit, Vyvron told you that before you paid, which is not nothing.

Who should walk away

You want tirzepatide. There is no monthly plan, the entry price is $790 in one charge, and a tirzepatide-first shopper is better served almost anywhere else — see tirzepatide cost without insurance for what the rest of the market charges. You are in Mississippi and want a compounded GLP-1. You budget in calendar months and would rather not discover a thirteenth charge. Or you want a named pharmacy and a prescriber you can look up, in which case start with The Edit and work down. Flexibility, which is where this provider is weakest, is one of the six factors the quiz will reweight for you.